Navigation Links
Steven Zecola Files a Citizen's Petition with the FDA for a New Approach to Address Metastatic Cancer
Date:6/24/2013

Washington, DC (PRWEB) June 24, 2013

Cancer causes over 550,000 deaths in the United States each year 1_/, and 90% of those deaths derive from metastatic cancer. 2_/ Yet, only 8% of the federal funding for cancer goes toward metastatic cancer. 3_/

Additionally, under the FDA’s procedures for clinical trials, a new drug takes 12 years on average to make it through the FDA process 4_/ at an average cost of over $1 billion. 5_/

The burden imposed by the FDA’s rules is even greater for the compounds designed to treat metastatic cancer. First, the FDA’s rules require the compounds to reduce the primary tumor, but that is not the purpose of these compounds and they often do not pass this test. 6_/ Second, the objective of the compounds is to delay the recurrence of cancer, which by definition implies an even further elongated trial approval process and even more costs.

Nor does the FDA recognize the poor prognosis of metastatic cancer patients to establish distinct procedures for clinical trials with these participants. 7_/ Yet many of these patients have been told to get their affairs in order and many would be willing to take greater risks than others to participate in research. But the FDA applies its standard safety guidelines to the trials with these patients which cover six categories of safety including adverse events unrelated to the drug. 8_/

The Petition requests the FDA to adopt procedures specific to the circumstances surrounding metastatic cancer. For example, the trial design to ensure a compound’s efficacy would be limited to two phases. _9/

With the requested changes in place, the journey to finding a cure for metastatic cancer can begin in earnest.

The Petition can be read at: http://www.regulations.gov/#!documentDetail;D=FDA-2013-P-0695-0001

Th
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Director of Proteomics at the Broad Institute of MIT and Harvard, Steven Carr, to Deliver Pittcon 2014 Wallace H. Coulter Plenary Lecture
2. Representatives Betty McCollum (MN) and Steven LaTourette (OH) to Receive USGS Coalition Leadership Award
3. Ceres Expands Board of Directors with former BP Chief Scientist and Undersecretary of Energy Steven Koonin
4. Stevenage Bioscience Catalyst to Welcome Cambridge University Researchers
5. Stevenage Bioscience Catalyst Opens With Exciting Year Ahead
6. Cellular Dynamics International Files Registration Statement for Proposed Initial Public Offering
7. Dr. Rongxiang Xu, Patent Owner of Damaged Organ Regeneration, a Top Priority Addressed in the 2013 Presidential State of The Union, Files Lawsuit Against Dr. Yamanaka for Deception
8. Dr. Rongxiang Xu, Patent Owner of Damaged Organ Regeneration, a Top Priority Addressed in the 2013 Presidential State of The Union, Files Lawsuit Against 2012 Nobel Laureate Dr. Yamanaka for Deception
9. 3SBio Inc. Files Annual Report on Form 20-F for Fiscal Year 2012
10. Early Stage Drug Delivery Technologies: 62 Profiles of Start-ups and Emerging Companies
11. Regado Biosciences, Inc. Files Registration Statement for Proposed Initial Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/13/2014)... December 13, 2014 QuickSTAT is making ... and Cold Chain capabilities, and is delighted to announce ... France, to serve Life Science clients in the region. ... a controlled-ambient warehouse, will provide 24/7 transportation and logistics ... investigational drugs, patient-clinical specimens, API, following IATA rules and ...
(Date:12/13/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/6p4j9m/glucose_sensors ) ... Sensors: the Next Generation" report to their ... The convergence of small-scale electronics and ... a better future to millions of diabetes patients ... levels accurately and reliably have the capability to ...
(Date:12/13/2014)... and SAN ANTONIO , Dec. ... today announced the presentation of data at the San ... EPO-ANE-3010 study evaluating epoetin alfa plus best supportive care ... patients with metastatic breast cancer receiving standard chemotherapy. This ... was to rule out a 15 percent or greater ...
(Date:12/12/2014)... 2014 Graphite Metallizing Corporation, the manufacturer ... and process equipment, has appointed Kirk Staller as Sales ... Canada. Staller holds a B.S. degree from Purdue University ... market place, much of it with a manufacturer of ... Michigan office. , “We are pleased to ...
Breaking Biology Technology:Quick Opens Office in France to Serve Life Science Community In France and Neighboring French-Speaking Countries 2Glucose Sensors: the Next Generation 2Glucose Sensors: the Next Generation 3Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 2Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 3Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 4Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 5Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 6Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 7Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 8Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 9Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 10Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 11Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 12Kirk Staller Joins Graphite Metallizing Corporation 2
... 2012 , Point-of-Care Diagnostics Initiative is ... by Bill & Melinda Gates Foundation and Grand Challenges Canada ... aid effort to create a low-cost portable testing platform for ... Development expected to be completed by 2014, enabling rapid ...
... 3, 2012 Profil® Institute for Clinical Research, Inc., ... diabetes and obesity, announced today record growth in the ... also reports an increase in the number of mid-size ... the largest global pharmaceutical companies, driven by a strong ...
... Therapeutics Plc (AIM: SLN), a leading international RNAi ... , has announced it has amended its existing exclusive Licensing ... a Phase 2a clinical study to assess the effect of ... patients with moderate and advanced Open-Angle Glaucoma (OAG). PF-655 incorporates ...
Cached Biology Technology:QIAGEN Joins Grand Challenges in Global Health Initiative to Bring Advanced Point-of-Care Diagnostics to World's Poorest Countries 2QIAGEN Joins Grand Challenges in Global Health Initiative to Bring Advanced Point-of-Care Diagnostics to World's Poorest Countries 3QIAGEN Joins Grand Challenges in Global Health Initiative to Bring Advanced Point-of-Care Diagnostics to World's Poorest Countries 4QIAGEN Joins Grand Challenges in Global Health Initiative to Bring Advanced Point-of-Care Diagnostics to World's Poorest Countries 5Profil Institute Reports Record Growth in Number of Clinical Trials in the Pipeline 2Profil Institute Reports Record Growth in Number of Clinical Trials in the Pipeline 3Silence Therapeutics' Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silence's AtuRNAi in a New Indication 2Silence Therapeutics' Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silence's AtuRNAi in a New Indication 3Silence Therapeutics' Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silence's AtuRNAi in a New Indication 4Silence Therapeutics' Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silence's AtuRNAi in a New Indication 5
(Date:12/10/2014)... Dec. 9, 2014  Valencell, a leader in performance ... a staggering demand from its licensees for highly accurate, ... is not solely coming from fitness and health sectors, ... "A wearable is only as useful as the ... the ultimate driver in long-term mass consumer adoption of ...
(Date:12/10/2014)... , December 9, 2014 ... BCARD Platform   ... meeting scheduling solutions for business-to-business (B2B) events, today ... leader in mobile near-field communication (NFC), Bluetooth low ...      (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will ...
(Date:12/3/2014)... 2, 2014   Marvin Test Solutions , ... solutions for military, aerospace, and manufacturing organizations, today ... successful TS-900 PXI semiconductor test platform . ... high-end systems to customers at a fraction of ... traditional ATE. "Our semiconductor customers ...
Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3
... A team of researchers from the Hawai,i Institute ... map of corals and zooxanthellae as part of a ... provides global-scale biological and ecosystem information on symbiotic zooxanthellae ... that live inside the cells of other marine organisms ...
... University of Maryland School of Medicine researchers have uncovered ... understanding cardiac arrhythmia and other heart muscle problems. Understanding ... open the door to new treatments. The study, published ... electrical impulses that coordinate contraction in heart and skeletal ...
... Scientists are reporting the development and successful tests in humans ... from exhaled breath, an advance that they describe as a ... non-invasive test for MS -- the most common neurological disease ... ACS Chemical Neuroscience . Hossam Haick and colleagues report ...
Cached Biology News:An online global map of coral and zooxanthellae data for climate change study is released 2An online global map of coral and zooxanthellae data for climate change study is released 3UM School of Medicine finds new pathway critical to heart arrhythmia 2UM School of Medicine finds new pathway critical to heart arrhythmia 3Advance toward a breath test to diagnose multiple sclerosis 2
Rabbit polyclonal to Somatostatin 28 ( Abpromise for all tested applications). entrezGeneID: 6750 SwissProtID: P61278...
... well Magnetic-Ring Stand is designed for paramagnetic ... microplates. The stand has a plastic base ... plate footprint. The use of 96 extremely ... easy magnetic separation. With this magnetic stand, ...
... DNA polymerase from Thermus aquaticus expressed in ... 1 tube of 250 units enzyme/tube and ... DNA), is the same enzyme as AmpliTaq ... a proprietary separation process to ensure that ...
Recombinant DNA polymerase from Thermus aquaticus expressed in E. coli; 5 units/L; 1 tube of 1, 000 units enzyme/tube w/Buffer II and MgCl2...
Biology Products: